A b s t r a c t
Introduction
Colorectal cancer (CRC) is the second cause of death due to cancer in Poland. According to estimates, 15,000 new cases and 11,000 deaths are observed in both sexes every year. Many patients do not have symptoms at diagnosis; however, it is estimated that 7-29% report with colorectal obstruction or it develops in the course of disease. Malignancies account for approximately 85% of causes of colorectal obstruction, and they usually indicate locally and systemically advanced disease. The traditional approach to treat such patients included a surgical procedure with resection and a primary anastomosis or a two-stage procedure involving initial resection followed by final colostomy (Hartmann's procedure) and subsequent restoration of the gastrointestinal tract continuity. However, both approaches are associated with several limitations: a single procedure is more difficult from a technical point of view or impossible due to intestinal wall damage, and only 40% of patients with malignant left-sided colon ob-struction are eligible for such a procedure. Usually, when left-sided colon obstruction is present, it is necessary to perform a two-stage procedure, and patients in this group are often elderly, with many concomitant diseases and with more advanced disease, and therefore with a higher risk of postoperative complications. As a result, it is often not possible to perform a second procedure to close the fistula; hence permanent colostomy is present and it negatively affects the quality of life.
Irrespective of the surgical method being used, surgical treatment of malignant colorectal obstruction is associated with prolonged hospitalisation, and the postoperative mortality rate is approximately 5-11%. Due to these problems, more and more interest has been shown in more modern, less invasive alternative methods and methods preceding surgical treatment: prosthesis implantation, laser ablation, argon plasma coagulation, endoscopic dilation, cryotherapy, electrocauterisation and endoscopic administration of agents resulting in tumour necrosis. Based on these comments, prosthesis implantation seems to be a leading endoscopic method used currently in palliative or preoperative treatment.
In 1990 Dohmoto was the first to publish a description of enteral stent implantation. He used a metal endoprosthesis in order to restore intestinal patency in a patient with unresectable colorectal cancer. In 1994 Tejero et al. presented a case when an enteral stent was used in a patient with resectable colorectal cancer complicated by obstruction. It was the first time that a stent was used to decompress the intestines and to prepare a patient for resection [1] [2] [3] [4] .
Between 1990 and 2012, more than 65 studies on the results of metal prosthesis implantation in palliative treatment and as a graft for surgical treatment of colorectal cancer were published.
Construction of the stent was preceded by several years of experience in stent implantation and constructions from various companies. From the very beginning, we used stents from the Czech company ELLA, including the Danis stent to control haemorrhage from oesophageal varices. In our opinion, the balloon positioning system used in these stents is based on the idea of the usage of the Sengstaken-Blakemore tube. In our stent the main idea of using the balloon for accurate positioning of stenosis was its good visibility on X-ray, which is missing in the Danis stent. The use of the second channel to provide a contrast agent outside the balloon allows one to specify the position of the set. This ensures safety during implantation as perforation of the gastrointestinal tract or abnormal position of the intestine after previous operations can be excluded. The Danis stent does not have such solutions and thus may result in incorrect stent positioning.
As a result of advances in the field of endoscopic methods and technological progress with regard to construction of new materials, it was possible to use nitinol stents. Nitinol is an alloy of nickel and titanium, and it is characterised by excellent elasticity and autonomous memory of its primary shape.
Aim
The study aimed to compare the results of implantation of traditional stents with results of implantation of an own stent using minimally invasive methods.
Material and methods
Traditional enteral stents have been used since 2009. Based on our own experience regarding stent implantation due to malignant colorectal obstruction, a decision was made to manufacture a self-constructed enteral stent. Work started in 2010, and Balton was the company that manufactured the first Polish enteral stent. Designs of stents by leading global manufacturers were considered when a self-constructed stent was designed. The rule was to use the best materials and to eliminate defects of stents available on the market. Implantation of a self-constructed expandable stent was performed in 45 subjects. Forty-five stents with the diameter of 25 mm and length of 60-80 mm were implanted in the period 2012-2014.
Left-sided colon obstruction due to cancer was an indication for transplantation. All patients were over 70 years old and had serious concomitant diseases. The Bioethics Committee at the Medical University of Warsaw approved the stent usage. A control group included 50 patients with colorectal cancer who received traditional stents in the period 2009-2011. In both groups uncoated stents were used.
Tumour stenosis consists of three sections: the critical stenosis, the tumour mass narrowing above and below the obstruction, and the obstruction caused by swelling of the intestinal wall located proximally and distally to the tumour.
Based on the numerous computed tomography studies it is considered that to cover the entire length of the stenosis, stents of two dimensions are needed: 6 cm and 8 cm. By covering the entire length of the stenosis and obstruction of the tumour it prevents restenosis.
Our stent covers only the internal length of a tumour. It is an innovatory approach, as traditional enteral stents have, apart from the main tube used to expand the tumour, two flares, distal and proximal, that exceed the tumour lumen significantly. They function as elements preventing stent migration. They expand in the lumen of the healthy intestine and a priori irritate and damage the distal mucosa and the mucosa of the intestine above the stenosis, after evacuation.
For that reason, our stent is not equipped with anti-migration flares. However, there is consequently a higher risk of stent migration. For this reason we developed our own, first ever, system of hooks that are responsible for permanent anchorage of the stent within a tumour mass (Photo 1). They are located in the centre, opposite to one another. The length of the hooks was designed so that there would not be a risk of intestinal perforation but at the same time the hooks would secure the stent at the site of the obstruction safely. According to an intraoperative assessment of the intestinal wall thickness performed in 50 patients, the minimum intestinal thickness was between 5 mm and 4.7 cm at the site of a tumour. Hooks of a self-constructed stent were 3 mm long. It is a safe length so perforation is not possible, and it is also sufficient to anchor the stent securely in the intestinal wall.
In order to deploy the stent safely at the site of obstruction, it has to be well visible under X-ray monitoring. Tests of stent visibility were conducted and X-ray scans of various braided stent designs were taken. As stent implantation in the intestinal lumen is a dynamic procedure that constantly changes along with intestinal peristalsis and respiratory movements, stent visibility was enhanced by placing distal and proximal markers of higher radiopacity. Additionally, at the site of anti-migration hooks, markers located in the central part of the stent were placed in order to facilitate their precise deployment in a tumour mass (Photo 2).
A possibility of precise stent implantation at the site of obstruction constitutes an original modification in the stent design. It is possible thanks to the design of the distal part of the delivery system with the stent. The system ends with a 5-mm bulb tip that enables free and atraumatic passage through the obstruction site under X-ray monitoring (Photo 3). X-ray monitoring was used to identify stenosis for stent implantation in low-lying tumours, while endoscopy was used in high-lying tumours. Savary-Gilliard dilators were used only in case of ability to pass the stenosis. In those cases, the expansion was continued only until the set could be placed safety.
At its base there is a folded stent, and inside there is a catheter ending with a balloon. The balloon is hidden at the base of the bulb tip while being deployed. When the stent passes through the obstruction, the balloon is filled with a radiopaque contrast agent that is visible under X-ray monitoring during an examination. The moment when the stent passes through a stenosis is also visible, as a conPhoto 1. Hooks Photo 2. Marker trast agent is administered into the system and it spreads on its upper surface when it has passed a critically narrowed tumour segment. The base of an expanded balloon is located in the direct vicinity of the stent (Photo 4). When the system is withdrawn, the balloon base is supported on the initial segment of a malignant stenosis. At this moment we start to release the stent located below. The stent length is selected according to stenosis length assessed based on a computed tomography scan performed prior to the procedure. As a result of positioning a cancer stenosis site with a balloon filled with a contrast agent, it is possible to precisely determine a site of a cancer stenosis and to deploy the stent covering only the internal surface of the tumour. When the stent has been released, the balloon with contrast agent is emptied and removed along with the system under radiologic supervision. However, a contrast agent is administered earlier in order to check stent expansion.
Results
Stents were applied in palliative treatment, obstructive colorectal cancer carcinoma and as a stage procedure prior to scheduled surgery. Implantation technical and clinical success defined as effective decompression of intestinal obstruction was 100% in both groups. There were 2 cases of stent migration in the control group. In both cases the stent location changed due to reduced tumour mass and intestinal inflammation following chemotherapy. There were also two cases of intestinal perforation in the control group. In both cases perforation was observed 27 and 35 days after implantation. During surgery the perforation in both cases developed at the site where the intestine was constantly irritated by the upper flare. In our opinion, this type of complication is strongly affected by the intestinal flexure above the tumour due to adhesions associated with previous operations (Table I) .
Resection surgery after intestinal decompression was performed in 67% in the study group and in 76% in the control group. A primary anastomosis was performed in all patients considered eligible for surgery. In 15% of patients in the control group jejunostomy was created in order to decompress a primary anastomosis. It included patients with rectal cancer, and the cause of decompressing jejunostomy included inflammation of the rectal mucosa due to irritation caused by a lower stent flare and fear of leakage at the anastomosis site (Table II) .
Discussion
Recently, efforts have been made to avoid emergency CRC surgery. There have been attempts of colonoscopic intestinal decompression in cases of obstruction, and in some centres self-expandable stents are implanted in the intestine at the site of stenosis. As a result, it is possible to decompress the intestine and to gradually prepare a patient for a scheduled procedure, increasing its chances of success [5] [6] [7] . In the case of a serious general condition or advanced cancer, stent implantation may be good and sufficient palliative treatment. According to reports, stents in such cases were present in the intestine for 2 to 64 weeks [8, 9] . Martinez-Santos et al. compared emergency surgical treatment with intestinal decompression with stents in patients with Photo 4. Release the stent located below balloon Photo 3. System ends left-sided colorectal obstruction due to cancer. Stents were used in order to delay surgery or as palliative treatment. They found that symptoms of obstruction regressed in 95% of cases after 8 to 96 h, 36.4 h on average. As a result, in patients in whom it was possible to wait and perform surgery as scheduled, intestinal resection and a primary anastomosis were performed statistically significantly more often (p < 0.0025) compared to patients operated on as an emergency (88% vs. 46%), and Hartmann's procedure was performed more rarely (p < 0.0025) (12% vs. 54%); additionally, their hospitalisation was shorter, as well as stay at the intensive care unit (ICU), and there were fewer postoperative complications in this group [10] .
Surgical treatment for colorectal cancer in the elderly is associated with a mortality rate of 1.0-25% (Table I) [6, [11] [12] [13] [14] [15] [16] . Papers comparing CRC treatment in the elderly and in younger patients reported that the mortality rate in the elderly is statistically significantly higher [5, 15, 17] . The complication rate in this group is significantly increased due to malignant colon obstruction. Therefore, as a result of using stents to decompress the intestine, it is possible to gain more time to prepare a patient, and to improve their clinical status. Surgery performed for malignant colorectal obstruction often has two stages. The first is a life-saving procedure to remove the tumour and create an ostomy. The second stage is performed several months later and it includes restoration of the gastrointestinal tract continuity [12] . Based on our experience, the second stage of surgical treatment is not performed in patients aged over 70 years. Advanced cardiovascular and respiratory disease ASA grade III/IV is usually the most common reason why patients are not considered eligible for surgery [8, 13, [18] [19] [20] [21] [22] [23] [24] . Therefore, good condition of the intestines subject to an anastomosis is a key factor when considering eligibility of patients for surgery. With regard to traditional stents, anti-migration flares reaching far outside the tumour mass are responsible for constant irritation leading to inflammation. Constant irritation may result in intestinal perforation. In our material this complication was observed in 2 patients in the control group. During an operation we observed perforation at the site where a stent anti-migration flare was in contact with the intestine that was positioned not in an anatomical position due to previous surgery. This complication was not observed in a group with a new stent implanted, and it can be explained by the fact that this stent covers only the tumour mass. Stent migration is the second most common complication associated with implantation. It is present in 1-11% of cases. Systemic oncological treatment reducing tumour mass and radiation therapy are thought to be the main causes of migration. Other causes of migration might include implantation of coated stents. In our material we observed migration in 2 (4%) patients in a traditional stent group. Migration was observed after chemotherapy had been completed, 5 and 7 months after implantation. In our opinion, lack of stent migration in patients in whom a self-constructed stent was implanted is associated with the presence of anti-migration hooks that provide secure anchorage for a stent inside a tumour. We believe the lack of complications in the study group is due to experience gained before the new stent was introduced.
Sixty-seven percent of patients in the study group and 76% of patients in the control group were operated on when the obstruction had regressed and their general condition had improved. A primary anastomosis was performed in all patients in both groups, after an appropriate resection was performed (Table II) . Colonoscopy was performed in Table I . Indication -palliative and bridge to surgery and complications all patients prior to surgery to assess stent location and to evaluate the whole colon. The examination in the control group revealed inflammation of the intestinal mucosa below and above the tumour that was caused by irritation due to anti-migration flares following intestinal decompression. It was not significant in cases where the tumour was located above the rectum, as the resection included the whole pathologically changed intestinal segment. However, if the tumour is located in the rectum, each centimetre of the healthy intestine is valuable in order to create a tight anastomosis. In 6 (15%) patients in the control group, jejunostomy was created to decompress an anastomosis due to inflammation observed during colonoscopy. The fistula was closed after 4 weeks. The surgery was preceded by colonoscopy of the area of the anastomosis.
Conclusions
When a stent is implanted in the sigmoid-rectal area, it is possible to achieve a secure surgical anastomosis after intestinal decompression. Stent implantation is fast and safe thanks to the positioning system that was used. The use of labelled hooks is a secure anti-migration solution.
